Stephen Wilson joins Cytocom to serve as head of global innovation

Stephen Wilson joins Cytocom to serve as head of global innovation

FORT COLLINS -- Cytocom, Inc . announced Stephen Wilson has joined the company as its head of global innovations, effective April 19. Wilson arrives at Cytocom after spending nearly 25... Read More

Wednesday April 21, 2021 Tags: Fort Collins, Cytocom, Stephen Wilson, Mike Handley

Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19

Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19

FORT COLLINS -- Cytocom, Inc. announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety... Read More

Thursday March 18, 2021 Tags: Fort Collins, Cytocom, CYTO-205, Michael Handley, FDA

Cytocom in proposed merger with Cleveland BioLabs after SEC filing

Cytocom in proposed merger with Cleveland BioLabs after SEC filing

FORT COLLINS/ BUFFALO, N.Y. -- New York-based Cleveland BioLabs, Inc. (NASDAQ: CBLI), a biopharmaceutical company developing novel approaches to activate the immune system, filed a registration... Read More

Thursday February 18, 2021 Tags: Fort Collins, Cytocom, Cleveland BioLabs, Michael Handley

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19

FORT COLLINS -- Cytocom, Inc. today provided an update regarding its CYTO-200 portfolio of clinical programs. Cytocom said it has submitted an Investigational New Drug (IND) application with... Read More

Tuesday February 16, 2021 Tags: Fort Collins, Cytocom, COVID-19, CYTO-205, Michael Handley